ACOG Practice Advisory: Maternal Respiratory Syncytial Virus Vaccination

This Practice Advisory was developed by the American College of Obstetricians and Gynecologists with the assistance of Kevin A. Ault, MD, Brenna L. Hughes, MD, and Laura E. Riley, MD.

This Practice Advisory provides guidance for the use of respiratory syncytial virus (RSV) vaccine during pregnancy for the prevention of severe RSV disease in young infants. Pfizer’s RSVpreF vaccine (trade name Abrysvo) is the first and only RSV vaccine approved by the U.S. Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC) for use during pregnancy to prevent severe illness in young infants.